logo-loader
viewAlgernon Pharmaceuticals Inc.

Full interview: Algernon Pharmaceuticals updates Phase 2 human testing of Ifenprodil for COVID-19

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joins Steve Darling from Proactive Vancouver to provide an update that a protocol is planned for a  physician initiated phase 2 clinical study of NP-120 for COVID-19 infected patients in South Korea.

Moreau telling Proactive how they are fast tracked for this trial and what the next steps will be.

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.405 CAD

CSE:AGN
Market: CSE
Market Cap: $44.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Curtis Banks' transition to a more sustainable, resilient business model

Curtis Banks Group Will Self talks to Proactive London's Katie Pilbeam about their trading and operations update. He says they have continued to invest in the business committing £5m to investment in technology, over a 5 year period. The company has already delivered a new online portal,...

6 hours, 48 minutes ago

2 min read